0001004878-11-000421.txt : 20111206
0001004878-11-000421.hdr.sgml : 20111206
20111205182752
ACCESSION NUMBER: 0001004878-11-000421
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20111205
ITEM INFORMATION: Termination of a Material Definitive Agreement
FILED AS OF DATE: 20111206
DATE AS OF CHANGE: 20111205
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 111244108
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8ktermatmdec11.txt
8-K RE TERMINATE ATM
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 5, 2011
CEL-SCI CORPORATION
-------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 0-11503 84-0916344
-------------------- -------------------- ----------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
-------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-----------------------------
(Former name or former address if changed since last report)
Item 1.02 Termination of a Material Definitive Agreement
On December 9, 2010 CEL-SCI Corporation (CEL-SCI) entered into an At the
Market Issuance Agreement with McNicoll Lewis & Vlak LLC, or MLV, under which
CEL-SCI may offer and sell shares of its common stock, having an aggregate
offering price of up to $30,000,000 million from time to time through MLV acting
as agent and/or principal.
On December 5, 2011 CEL-SCI, per the terms of the agreement, CEL-SCI
exercised its right to terminate the agreement.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 5, 2011 CEL-SCI CORPORATION
By: /s/ Patricia Prichep
-------------------------------------
Patricia Prichep, Senior Vice President
of Operations
3